In this week’s edition of InnovationRx, we look at a new AI drug development deal, a pill for sleep apnea, Commure’s $7 billion valuation, and more. To get it in your inbox, subscribe here.
Genesis Molecular AI’s Evan Feinberg (left) and Incyte’s Pablo Cagnoni
Genesis Molecular AI and Incyte
Continue Reading
Leave a Reply